8-K: CytoSorbents Reports Q3 2026 Results, Achieves Cash Flow Breakeven

CytoSorbents Corporation announced third quarter 2026 financial results, reporting a 3% revenue increase to $9.7 million and achieving operating cash flow breakeven.

Summary

• CytoSorbents Corporation reported third quarter 2026 revenue of $9.7 million, a 3% increase from $9.5 million in Q3 2025, driven by a 16% rise in distributor and strategic partner sales.
• Gross margin improved to 75% in Q3 2026, up from 73% in Q2 2026 and 70% in Q3 2025.
• Total operating expenses decreased by 11% to $8.5 million in Q3 2026 compared to $9.5 million in Q3 2025.
• Operating loss improved by 59% to $1.2 million, and net loss narrowed by 42% to $1.8 million ($0.58 per share) in Q3 2026.
• Adjusted EBITDA loss improved significantly by 86% to $0.3 million in Q3 2026, compared to a loss of $2.0 million in Q3 2025.
• The company achieved operating cash flow breakeven, generating approximately $43,000 in positive operating cash flow (excluding restructuring payments) in Q3 2026.
• Total cash, cash equivalents, and restricted cash was approximately $5.7 million as of September 30, 2026.
• For the first nine months of 2026, revenue was $28.2 million, and net loss was $11.4 million ($3.62 per share).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, highlighting significant operational improvements and strategic progress, though continued losses and market access challenges remain.

Positives

• Achieved operating cash flow breakeven in Q3 2026, a key financial milestone.
• Revenue increased by 3% to $9.7 million in Q3 2026, with distributor and strategic partner sales up 16%.
• Gross margin improved to 75% in Q3 2026.
• Operating expenses decreased by 11% in Q3 2026.
• Operating loss improved by 59% to $1.2 million in Q3 2026.
• Net loss improved by 42% to $1.8 million in Q3 2026.
• Adjusted EBITDA loss narrowed by 86% to $0.3 million in Q3 2026.
• Progress made on advancing the DrugSorb-ATR De Novo submission to the FDA, with a new submission planned for early 2027.

Negatives

• The company reported a net loss of $1.8 million for Q3 2026.
• Total cash, cash equivalents, and restricted cash was $5.7 million as of September 30, 2026, a slight decrease from $5.9 million at June 30, 2026.
• Sales in Germany decreased by 20% year-over-year, impacting overall revenue growth.
• The company has a substantial accumulated deficit of $323.6 million as of September 30, 2026.
• The company's total liabilities ($39.5 million) exceeded its total assets ($37.2 million) as of September 30, 2026, resulting in a stockholders' deficit.

Risks

• The company's ability to regain and maintain compliance with Nasdaq continued listing requirements.
• The company's ability to appropriately finance the Company, including the extension, refinancing or repayment of existing debt.
• The company's ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval for DrugSorb-ATR.
• The company's ability to sustain operating cash-flow breakeven.
• The company's ability to develop and commercialize its products and product candidates, including securing necessary funding and strategic partnerships.
• The company's restructuring of its direct sales team and strategy in Germany.
• The company's ability to attract, retain and effectively integrate qualified personnel.

Future Outlook

The company aims to sustain operating cash flow breakeven, restore profitable growth in its core CytoSorb business, advance DrugSorb-ATR towards U.S. commercialization, and unlock the strategic value of HemoDefend-BGA. These four drivers are expected to create multiple pathways for shareholder value creation.

Management Comments

• "The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments," stated Dr. Phillip Chan, Chief Executive Officer.
• "This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business."
• "Importantly, every dollar of operating cash burn we eliminate helps reduce our future financing needs and positions us to capture more of the potential value of future growth for our shareholders."
• "With operating cash flow breakeven achieved and a more efficient cost structure in place, CytoSorbents is entering its next phase from a stronger operational position."
• "Our priorities are clear: sustaining financial discipline, restoring profitable growth in our core CytoSorb franchise, advancing DrugSorb-ATR toward U.S. commercialization, and unlocking the strategic value of HemoDefend-BGA."

Industry Context

StockSavvy.ai notes that CytoSorbents operates in the critical care and cardiac surgery blood purification market, a niche but vital segment. The company's focus on removing toxins and inflammatory agents aligns with broader trends in critical care medicine aimed at improving patient outcomes in life-threatening conditions. The pursuit of FDA approval for DrugSorb-ATR positions them to enter the significant U.S. market, a key competitive battleground for medical device companies.

Comparison to Industry Standards

• The reported gross margin of 75% is strong for a medical device company, indicating efficient production and pricing power for its core product.
• The improvement in operating loss and adjusted EBITDA loss demonstrates progress in cost management, a critical factor for companies in the development and commercialization phase.
• Achieving operating cash flow breakeven is a significant positive step, though many companies in this sector may still be in a cash burn phase while investing heavily in R&D and market expansion.
• The company's strategy of pursuing multiple value drivers (core product growth, new market entry, platform technology development) is common among biotech and medtech firms seeking diversified growth.

Stakeholder Impact

• Shareholders: Potential for increased value creation through sustained operating cash flow, profitable growth, and successful market entries for new products.
• Employees: The company's restructuring and focus on efficiency may impact workforce dynamics, while progress in key projects could lead to future growth opportunities.
• Creditors: Improved cash flow and reduced losses are positive for debt servicing, though the company's liabilities still exceed assets.
• Customers: Continued product development and regulatory progress for DrugSorb-ATR could lead to new treatment options in critical care.

Next Steps

• Sustain operating cash flow at or near breakeven.
• Selectively invest to accelerate sales growth.
• Restore growth in the German market through targeted sales force expansion.
• Advance DrugSorb-ATR toward U.S. commercialization with a new De Novo submission in early 2027.
• Finalize an animal study protocol with the FDA for DrugSorb-ATR.
• Advance discussions with the FDA regarding data requirements for a De Novo submission for direct oral anticoagulant removal.
• Evaluate opportunities to advance and realize the value of HemoDefend-BGA through non-dilutive funding, partnerships, or licensing.

Key Dates

Recommendation

The company has demonstrated significant operational improvements, achieving cash flow breakeven and narrowing losses. However, the path to profitability and U.S. market access for key products like DrugSorb-ATR still involves substantial regulatory and execution risks. While the progress is encouraging, the current financial position and ongoing development needs warrant a 'hold' recommendation until further de-risking occurs.

Keywords

CytoSorb, blood purification, intensive care, cardiac surgery, DrugSorb-ATR, FDA, financial results, operating cash flow